Combined Hormonal Versus Progestin Only Contraception During Lactation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00374972 |
Recruitment Status
:
Withdrawn
(difficulty in recruitment. lack of sponsorship)
First Posted
: September 12, 2006
Last Update Posted
: May 16, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective: To determine and compare the effect of low dose estrogen combined hormonal contraceptives and progestin-only contraceptives on lactation.
The subjects will be drawn from a healthy obstetric population in each center, where possible preliminary contact during antenatal period. At the postpartum visit, subjects that express their wish for a hormonal contraceptive method will be offered enrollment. After obtaining an informed consent the participants will be allocated according to their free wish to either receive a combined preparation containing 0.02 mg ethylestradiol and 0.15 mg desogestrel (Mercilon, Organon) or a progestin only pill containing 0.075 mg desogestrel (Cerazette, Organon). Demographic, habits and perinatal data will be collected and stored to analysis.
Frequency and methods of observation: All women will be followed at 6 (baseline), 9 and 12 weeks post - partum. Instruction will be given as to recording information on intercurrent disease, frequency of nursing and use of complementary formula supplements. Maternal BMI calculation ( weight/height2) will be obtained at first visit.
The objective is to compare the capacity of the breast to secrete milk under standard conditions and evaluate the influence of different hormonal contraception means. Thus samples will be collected at 6 weeks (enrollment) and the 9 and 12 weeks visits. An Egnell pump will be used for a maximum of 20 minutes form from both breasts, simulating a regular breast feeding. A total of 10 ml aliquot will be taken for composition analysis and the rest will be offered to the infant. The milk volume/feeding will be estimated and expressed in ml/feeding and multiplied by the number of feedings reported.
Outcome variables: Milk volume, infant growth at each visit and biochemical markers of milk analysis : lipid, casein and carbohydrate content
Condition or disease |
---|
Lactation |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Time Perspective: | Prospective |
Actual Study Start Date : | June 2006 |
Actual Primary Completion Date : | January 2007 |
Actual Study Completion Date : | January 2007 |
Group/Cohort |
---|
combined contraceptives
combined contraceptives
|
pregesterone only contraceptives
pregesterone only contraceptives
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy
Exclusion Criteria:
- mothers to infants that their weight will be below the 10th percentile
- mothers to infants sensitive to milk

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00374972
Principal Investigator: | Naama Srebnik, MD | A resident at the Shaare Zedek Medical Center | |
Study Director: | Surina Grisaru-Granovsky | A senior doctor at the Shaare Zedek Medical Center |
ClinicalTrials.gov Identifier: | NCT00374972 History of Changes |
Other Study ID Numbers: |
40106 |
First Posted: | September 12, 2006 Key Record Dates |
Last Update Posted: | May 16, 2017 |
Last Verified: | April 2017 |
Additional relevant MeSH terms:
Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs |